To evaluate the safety and effectiveness of the ReFlow Medical Wingman Catheter used to cross de novo or restenotic infrainguinal CTOs that cannot be crossed with a standard guidewire.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Lesions With Successful CTO Crossing Assessed by Angiography
Timeframe: Intraprocedural
Major Adverse Event (MAE) Rate
Timeframe: Assessed from the time of the procedure through 30 days
Rate of Clinically Significant Perforations
Timeframe: Will be assessed from the time of the procedure through 30 days